These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 21541621

  • 1. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines.
    Emons G, Muller V, Ortmann O, Grossmann G, Trautner U, Stuckrad B, Schulz K, Schally A.
    Int J Oncol; 1996 Dec; 9(6):1129-37. PubMed ID: 21541621
    [Abstract] [Full Text] [Related]

  • 2. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
    Gründker C, Völker P, Emons G.
    Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells.
    Günthert AR, Gründker C, Böttcher B, Emons G.
    Anticancer Res; 2004 Jun; 24(3a):1727-32. PubMed ID: 15274347
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells.
    Emons G, Müller V, Ortmann O, Schulz KD.
    J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):199-206. PubMed ID: 9699874
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
    Gründker C, Emons G.
    Reprod Biol Endocrinol; 2003 Oct 07; 1():65. PubMed ID: 14594454
    [Abstract] [Full Text] [Related]

  • 11. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV.
    J Clin Endocrinol Metab; 1993 Dec 07; 77(6):1458-64. PubMed ID: 8263128
    [Abstract] [Full Text] [Related]

  • 12. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD, Schally AV.
    Cancer Res; 1993 Nov 15; 53(22):5439-46. PubMed ID: 8221683
    [Abstract] [Full Text] [Related]

  • 13. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR, Gründker C, Bongertz T, Schlott T, Nagy A, Schally AV, Emons G.
    Am J Obstet Gynecol; 2004 Oct 15; 191(4):1164-72. PubMed ID: 15507937
    [Abstract] [Full Text] [Related]

  • 14. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
    Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsasser HP, Nagy A, Schulz KD, Grundker C, Schally AV, Emons G.
    Int J Oncol; 2000 Nov 15; 17(5):1063-9. PubMed ID: 11029513
    [Abstract] [Full Text] [Related]

  • 15. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
    Günthert AR, Gründker C, Olota A, Läsche J, Eicke N, Emons G.
    Eur J Endocrinol; 2005 Oct 15; 153(4):613-25. PubMed ID: 16189183
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells.
    Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC, Lo TB, Schally AV, Lee MT.
    Int J Cancer; 2002 Jun 01; 99(4):505-13. PubMed ID: 11992539
    [Abstract] [Full Text] [Related]

  • 17. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma.
    Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G.
    Cancer Res; 1995 Feb 15; 55(4):817-22. PubMed ID: 7850795
    [Abstract] [Full Text] [Related]

  • 18. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145.
    Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P.
    J Clin Endocrinol Metab; 1996 Nov 15; 81(11):3930-7. PubMed ID: 8923840
    [Abstract] [Full Text] [Related]

  • 19. Differential inhibitory effects on human endometrial carcinoma cell growth of luteinizing hormone-releasing hormone analogues.
    Borri P, Coronnello M, Noci I, Pesciullesi A, Peri A, Caligiani R, Maggi M, Torricelli F, Scarselli G, Chieffi O, Mazzei T, Mini E.
    Gynecol Oncol; 1998 Dec 15; 71(3):396-403. PubMed ID: 9887238
    [Abstract] [Full Text] [Related]

  • 20. Growth-inhibitory actions of analogues of Luteinizing Hormone Releasing Hormone on tumor cells.
    Emons G, Ortmann O, Schulz KD, Schally AV.
    Trends Endocrinol Metab; 1997 Nov 15; 8(9):355-62. PubMed ID: 18406825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.